The Cube CYP2C19 test can be used to aid clinicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. Genomadix CubeTM CYP2C19 System identifies the CYP2C19 ...

The immediate impact for the medical sciences is unclear, but the symbolism is “very chilling,” one commentator says.

Insight from almost 100,000 cases at a single institution show physician practice can make a difference, even without new ...

A maladaptive stress response might be amenable to behavioral or other interventions to lower future CV risk, say researchers ...

Task force members say that continued collection of data will help build credibility of what is “fair market value” for ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

The ability to diagnose MI was better with troponin I, but T better predicted mortality. Both tests have strengths, ...

This year’s report shows risk factors on the rise, enduring racial and geographic gaps, and clues to the global picture, too.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.